0574 (0574) Fair Value & Analysis

Healthcare · Market cap HK$35.8M

0 0574 0574 · HK

PriceHK$0.0180

Fair ValueHK$0.0184

Upside+2.0%

Quality35/100

Evidence: Low Range HK$0.0184 – HK$0.0202

Fair value as of: Jul 2, 2026

From 6 valuation models · updated today

Share price −51.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0180 – HK$0.0539 · fair‑value band HK$0.0184 – HK$0.0202 · the HK$0.0180 price screens below the HK$0.0184 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0574 (0574) currently trades at HK$0.0180, while our model-based Fair Value estimate is HK$0.0184 — implying the stock looks roughly 2.0% undervalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, 0574 generated revenue of HK$86.8M at a net margin of -18.3%. Revenue grew 1.0% year over year. It earns a return on equity of -22.0%. Net debt stands at HK$40.0M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$86.8M

Revenue growth (YoY) +1.0%

Net margin -18.3%

Return on equity -22.0%

Free cash flow −HK$11.7M FY2025

Operating margin 16.4%

More key figures

EPS (TTM) HK$-0.0100

EPS growth (YoY) +684%

Net debt HK$40.0M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0574 reported revenue of HK$86.8M in FY2025 versus HK$86.4M in FY2021, a compound +0.1%/yr. Reported net income was −HK$15.9M in FY2025.

Revenue +0.1%/yr

FY21 HK$86.4M

FY22 HK$71.8M

FY23 HK$129M

FY24 HK$86.6M

FY25 HK$86.8M

Net income

FY21 −HK$54.4M

FY22 −HK$43.4M

FY23 HK$2.4M

FY24 −HK$15.3M

FY25 −HK$15.9M

Is 0574 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIY	$4.55	$8.78	+93%
Alibaba Health Information Technology Limited ALBBY	$8.27	$6.61	-20%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$17.76	R$14.97	-16%
Yifeng Pharmacy Chain Co 603939	¥19.75	¥40.59	+106%
Clicks Group CLCGY	$27.97	$34.29	+23%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0574 (0574) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0184 versus a price of HK$0.0180 — about +2% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0574?

Our model-based fair value for 0574 is HK$0.0184 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0180.

What is the quality score of 0574?

0574 has a Quality Score of 35/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0574 (0574)?

0574 reported trailing-twelve-month revenue of about HK$86.8M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0574?

The net profit margin of 0574 is about -18.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.